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REVERSAL OF RENAL ALLOGRAFT REJECTION WITH INTRAVENOUS 
METHYLPREDNISOLONE “PULSE” THERAPY 
NICHOLAS J. FII:DUSKA, M.D., .lERb;MIAH G. ‘l’1JRCOTTE, M.D., PAIJL W. GIKAS, M.D., 
GEORGE E. BACON, M.D., AND JOHN A. PENNER, M.D. 
REJECTION CONTINUES TO BE A 
MAJOR PROBLEM confronting the trans- 
plant recipient and his surgeon. Acute rejec- 
t,ion of renal allografts is commonly treated by 
increasing the daily oral dose of corticoster- 
aids. Multiple complications of this therapy, 
including gastrointestinal hemorrhage and in- 
creased susceptibility to infection, have been 
reported. Intermittent large-dose intravenous 
corticosteroid therapy has the theoretical, 
but still unproved, potential of halting rejec- 
tion while avoiding the toxicity associated 
with frequent oral administration. Intravenous 
corticosteroid therapy has been used by some 
clinicians to treat rejection [2, 41. However, 
many clinical transplant teams have not been 
convinced of the advantages of the i&rave- 
nous route and have continued to treat relet- 
tion by increasing the oral dose of corticoster- 
oids to 200-300 mg./day usually given in di- 
vided doses. A recent toxicologic study demon- 
strated that an even larger intravenous dose of 
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methylprednisolone sodium succinate, than 
has been used to treat rejection previously, is 
well tolerated by humans [9]. Our study deals 
with the use of very large intravenous doses of 
methylprcdnisolonc, that is 30 mg./kg., for 
treating allograft rejection in dogs and hu- 
mans. In addition, the circulating half-life of 
methylprednisolone using a highly specific gas 
chromatographic method was defined for the 
first time [l]. The notable absence of serious 
side effects, probably related to the relatively 
short circulating half-life of this drug when 
administered intravenously, and the ability of 
this dosage regimen to modify allograft rejec- 
tion are documented in this study. 
MATE’RIALS AND METHODS 
Fourteen beagles underwent bilateral recipi- 
ent nephrectomy and received renal allografts. 
Urine was collected in metabolic cages. Serial 
hematologic, coagulation, and blood and urine 
studies were obtained. Endogenous creatinine, 
inulin, and para-aminohippurate (PAH) 
clearances were determined. Serial biopsies 
were taken of the kidney allograft, spleen, 
mesenteric lymph nodes, and liver. Sections of 
these tissues were examined using hematoxy- 
lin-eosin and methyl green pyronin stains [7]. 
All studies were not obtained in every dog. 
Serial renal arteriograms were performed be- 
fore and after rejection in four dogs. No tech- 
nical problems or other operative complica- 
tions were cncountercd. All kidneys functioned 
promptly and serum creatinine was less than 
1.2 mg./lOO ml. 24 hours after transplantation 
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in all animals. Subsequent elevation of serum 
creatinine to 2.0 mg./lOO ml. or higher was 
interpreted as reflecting the onset of acute 
reject#ion. Each dog was then treated with an 
intravenous “pulse” of methylprednisolone, 30 
mg.,/kg., administered in 500 ml. of 5% dex- 
trose in 0.2% NaCl over 1 hour. To substanti- 
ate the diagnosis of reject.ion an open renal 
biopsy was performed just prior to administer- 
ing the pulse in 10 dogs. Frequent serum levels 
of met,hylprednisolone were determined using 
gas chromatography as described by Bacon 
during the 24 hours after administration of the 
pulse [l]. Serial studies were continued until 
death at, which time an autopsy was performed 
upon all dogs. 
One additional dog with a renal allograft 
was treated with four consecutive daily pulses 
of methylprednisolone 30 mg./kg. In this dog 
open renal biopsies were taken at the time of 
transplantation, immediately prior to each 
pulse and at autopsy. 
Similar serial blood and urine studies were 
obtained in six control dogs. Four dogs were 
used to study t,hc toxicology of intravenous 
mcthylprednisolone; two dogs received 15 
mg./kg., and two received 30 mg./kg. Two 
other dogs served as untreated controls; that 
is, they underwent bilateral recipient, nephrec- 
tomy, received renal allografts, and were stud- 
icd serislly, but. were not t.rcated for rejection 
with methylprednieolone. A seventh dog also 
.served as an untreated control. This animal 
underwent’ bilat,eral reripient nephrectomy, re- 
ceived a renal allograft, and underwent serial 
Olin renal biopsies at, the same times after 
transplantation as the dog treated with four 
ronsecutives pulses. Rejection in this dog, 
however, wa,s not treated wit’h methylpredni- 
solone. 
The records of 100 consecutive recipients of 
human renal allotransplants performed at the 
University of Michigan Medical Center be- 
tween ,June 18, 1969 and Oct. 20, 1971 were 
reriewcd and acute rejection episodes were 
identified. These episodes were defined as 
those occasions when an abrupt deterioration 
in renal function occurred in the absence of 
other possible explanations such as technical 
or infectious complications. Often other signs 
of rejection were present. These rejection epi- 
sodes were treated with single or multiple 
pulses of intravenous met’hylprednisolone 30 
mg.,/kg. given in 200 ml. of 5% dextrose in 
water over one-half hour. A pulse was re- 
peated every 48-72 hours for a maximum of 
three or four doses as needed to reverse rejec- 
tion. In most cases, the daily oral maint’enance 
dose of prednisone was also raised slightly, 
t,hat is, t’he maintenance dose was increased by 
25% or 10 mg., whichever was larger. 
RESULTS 
Animal Studies 
Elevation of serum creatinine to 2.0 mg./lOO 
ml. or higher, reflecting the onset of acute 
rejection, occurred 6.2 * 0.7 days after trans- 
plantation. The mean survival of dogs treated 
with a single pulse was 9.6 I+ 0.3 days. This 
did not differ significantly when compared 
with untreated control dogs. No clinical evi- 
dence of t,oxicity from the pulse, such as gae- 
trointestinal bleeding, was observed in an> 
dog. 
Hemntologic, Coagulation, Blood, and Urine 
Chemistry Studies 
x’o significant changes or biochemical evi- 
dence of toxicity consequent to methylpredni- 
solone pulse therapy were demonstrated in se- 
rial studies of hematocrit, white blood cell 
count, relative and absolute lymphocyt,e 
counts ; platelet count; prot.hrombin t.ime ; par- 
tial thromboplastin time; thrombin clotting 
time ; quantitative fibrinogen levels ; serum 
creatinine; blood urea nitrogen; serum sodium, 
potassium, chloride, carbon dioxide, and mag- 
nesium; bilirubin; serum glutamic oxalacetic 
transaminaae ; total serum protein and albu- 
min; or urine sodium, potassium, chloride and 
magnesium. The changes in blood studies ob- 
served in dogs treated with a pulse while un- 
dergoing rejection were similar to changes ob- 
served in untreated animals during rejection. 
Thr only changes observed in the four dogs 
not operated upon which received either 15 or 
30 mg.,‘kg. methylprednisolone intravenously 
was a rise in total n-hit? blood cell count and ;I 
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Table 1. Endogenous Creatinine Clearance 
in Liters/%$ HOUTS 
Dog 
Day 
Prior to Day of 





SMH-1 18.7 6.3 2.3 2.6 
SMH-2 20.6 3.6 1.4 3.2 
SMH-3 14.0 12.9 4.0 - 
SMH-4 13.0 7.0 11.0 - 
SMH-6 2.6 1.5 1.2 
SMH-8 28.9 9.4 8.5 5.6 
Mean 19.0 7.0 4.8 3.2 
SD fR.3 f3.8 IIJ13.3 f1.8 
Table 9. Glomerular Filtraiion, Rate as Delermined by 
In,ztlin, Clenrance in, Milliliters per Minute 
Dog Day of “Pulse” 
1 Day 2 Days 
After After 
“Pulse” “Pulse” 
SMH-3C 2.5 2.7 4.1 
SMH-4C 4.8 8.0 3.8 
SMH-AC 0.9 2.2 1.6 
Mean 2.7 4.3 3.2 
SD *a.0 f3.2 f1.4 
marked reduction in absolute lymphocyte 
count. 
Renal Clearance Studies and Renal Arterio- 
grams 
In six dogs endogenous creatinine clearance 
and in three dogs inulin and PAH clearance 
studies were obtained before and after pulse 
therapy. Creatinine clearance decreased pre- 
cipitously in most dogs between the day prior 
to pulse therapy and the day of pulse adminis- 
tration confirming that the rejection process 
was very active at this time (Table 1). Pulse 
therapy seemed to halt this trend as indicated 
by modest improvements in creatinine clear- 
ance in three of six dogs, inulin clearance in all 
three dogs studied, and PAH clearance in two 
of three dogs (Tables 2 and 3). The serial 
renal arteriograms obtained during rejection 
showed the typical progressive changes of 
rejection. No improvement was demonstrated 
in the arteriographic appearance of rejection 
subsequent to pulse therapy. 
Serum LDH 
Serum LDH levels were elevated at the time 
of therapy for rejection (Table 4). LDH was 
reduced in five of nine dogs treated with intra- 
venous methylprednisolone and the mean 
LDH level of the entire group of nine dogs 
treated with pulse was also reduced. These 
changes in LDH did not reach statistical sig- 
nificance in this small group of animals. 
Total Urine LDH, Urine Volume, and Osmo- 
lality 
Total urine LDH was also elevated at the 
time of therapy for rejection (Table 4). Total 
urine LDH excretion was reduced in six of six 
dogs within 48 hours after administration of 
methylprednisolone. Twenty-four-hour urine 
volume was increased in all eight dogs within 
48 hours after pulse therapy. The mean in- 
crease was 692 ml,, and the least increase ob- 
served was 490 ml.; in five dogs the magnitude 
Table 3. Renal Plasma Flow as Determined by Para- 
Aminohippurate Clearance in 




1 Day 2 Days 
After After 
“Pulse” “Pulse” 
SMH-YC 8.3 3.1 7.4 
SMH-4C 25.4 17.0 13.0 
SMH-6C 2.6 4.1 2.9 
Mean 12.1 8.1 7.8 
SD f11.7 zk7.7 Ik5.1 
Table 4. Serial Serum LDH, Crine LDH, Urine 




























467 f 378 
305 f 35 
3,611 zt 34,73( 
4,973 f 29,45( 
332 f 186 
299 f 115 
924 f 752 





337 f 127 
355 f 21 
14,964 & 20,440 
84,013 f 5,675 
1024 f 395 
276 rt 77 
449 f 211 
* LDH activity is expressed in B-B units. Urine 
volume is recorded as milliliters per 24 hours and 
urine osmolality is milliosmoles,/liter. Control ani- 
mals received renal allografts, but were not treated 
with methylprednisolone. 
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of the increase exceeded the 500-ml. volume of 
fluid administered intravenously as a vehicle 
for methylprednisolone. Urine osmolality 
dropped t,o a low level at t’he time of rejection, 
and in four dogs the urine osmolality increased 
within 48 hours after a single pulse. The 
standard deviations of these determinations 
were large and the numbers of animals rela- 
t’irely small; none of these changes in urine 
LDH, urine volume, or osmolality reached 
statistical significance. 
Histology 
Histologic evidence of rejection was present 
in the allografts of all 10 dogs biopsied imme- 
diately prior to “pulse” therapy. A striking 
reduction in the cellular infiltrate was noted in 
2 of 10 dogs biopsied 48 hours subsequent to 
“pulse” therapy (Figs. 1, 2, and 3). Both py- 
roninophilic and nonpyroninophilic cells were 
reduced. In biopsies taken at a later time the 
rejection process again progressed. In the other 
eight dogs biopsied after receiving a pulse no 
convincing improvement in the histology of 
rejection could be consistently substantiated 
in the multiple sections examined. Rejection 
proceeded relentlessly in the allografts of the 
two dogs which served as untreated controls; 
t#liere was a progressive accumulation of py- 
roninophilic and nonpyroninophilic cellular in- 
filtrate, necrosis of tubules and vessels, throm- 
bosis of vessels, and multiple hemorrhagic in- 
farcts. 
In the dog receiving four pulses at 24-hour 
intervals beginning on the fifth day after 
transplantation, a delayed but more sustained 
reduction of the cellular infiltrate in the renal 
allograft occurred. Significant reversal of the 
histologic pattern of rejection was first noted 
24 hours after the third pulse. The dog died 24 
hours after receiving the fourth pulse; this was 
9 days after transplantation. The serum creat- 
inine had remained below 1.0 mg./lOO ml. even 
in the sample drawn just shortly prior to 
deat’h. A kidney biopsy t’aken at autopsy ex- 
hibited relatively mild focal infiltrates of 
mononuclear cells. The cause of death was not 
apparent, but a wound infection was present. 
Biopsies of spleen, mesenteric lymph nodes, 
and liver were taken in 10 dogs at the time of 
renal transplantation, time of pulse treatment, 
48 hours subsequent to pulse, and at autopsy. 
These organs remained histologica,lly normal. 
Methylprednkolone Circulating Half-life 
Serial serum levels of methylprednisolone 
were measured in 13 dogs during the 24 hours 
after administration of a pulse. A high mean 
Fig. 1. Section of kidney (No. SMH-9) at the time of transplantation exhibiting no significant inflammatory 
cellular infiltrate. (Methyl green pyronin stain, X112). 
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Fig. 2. Section of kidney (No. SMH-9) 5 days after transplantation and immediately prior to methylprednisolone 
pulse showing an intense, diffuse cellular infiltrate. Much of this infiltrate is composed of pyroninophilic’ cells. 
(Methyl green pyronin stain, X112); 
Fig. 3. Section of kidney (No. SMH-9) 48 hours after methylprednisolone pulse showing an aggregate of pyronin- 
ophilic cells around a blood vessel. The cellular infiltrate is much less diffuse than depicted in Fig. 2. The re- 
duction in pyroninophilic cells is better appreciated in the original color slides. (Methyl green pyronin stain, 
X112). 
peak blood level of 1415 k 679 pg/lOO ml. was 
reached immediately after administration of 
the pulse (Table 5). The mean circulating 
half-life was 3.48 + 0.70 hours. The very high 
mean correlation coefficient of -0.93 -t 0.06 
when serial levels were correlated with time 
suggests that methylprednisolone is metabo- 
lied by a first-order reaction (Fig. 4). 
Autopsies 
Gross evidence of rejection was obvious in 
all renal allografts at autopsy. The grafts were 
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swollen, edematous, and hemorrhagic; areas of 
necrosis within the renal parenchyma were 
present and frequently the renal vessels were 
thrombosed. In several dogs purulent exudate 
was present at the renal biopsy sites. A special 
effort was made to identify possible toxic man- 
ifestations of steroid pulse therapy but none 
ivere found. In no dogs was gastrointestinal 
bleeding, gastric or intestinal ulcerations, or 
pulmonary infections demonstrated. 
Humnn Experience 
Xnety-eight episodes of acute rejection 
were identified in 100 consecutive renal 
allotransplant recipienk. In 90 of these epi- 
sodes, or 92% of the time, the rejection process 
~vas either-halted or reversed with pulse t,her- 
spy. Most of the patients received more than 
one pulse, but on several occasions rejection 
n~s promptly reversed with a single pulse. No 
complications occurred which could be attrib- 
uted to bliis therapy. 
Discussion 
The most common method used to treat 
acute rejection of renal allografts is to tempo- 
rarily increase the dose of corticosteroids. 
lvmally corticosteroids are administered orally 
in two or three divided doses each day. Other 
means to treat rejection, such as the use of 
local radiation therapy or administration of 
Tab/c 5. C'irculaling Half-life of Methylprednisolone 







1 -0.98 1301 3.83 
2 -0.99 2169 3.04 
3 -0.99 1644 3.52 
4 -0.96 2233 3.54 
5 -0.96 434 3.47 
6 -0.93 2282 3.04 
7 -0.83 1489 2.56 
8 -0.95 1528 4.15 
9 -0.86 335 4.41 
10 -0.99 1716 2.53 
11 -0.89 1306 4.88 
12 -0.95 409 3.18 
13 -0.85 1219 3.03 
Mean -0.93 1415 3.48 
SD 10.06 f679 f0.70 
1001 
01234567 HOURS 
Fig. 4. Circulating half-life of methylprednisolone in 
13 Dogs. The graph illustrates as an example serial 
serum levels of methylprednisolone and the half-life 
as determined in dog No. SMH-1. In the box below 
are indicated the mean half-life and mean correla- 
tion coefficient for 13 dogs. 
antilymphocyte globulin, arc probably less 
effective and have been used only as adjuncts. 
Unfortunately, current methods to reverse 
rejection are not always successful and the use 
of high doses of corticosteroids is frequently 
associated with significant complications. In- 
deed, it, has been common for recipients of renal 
allografts to die from complications secondary 
to immunosuppressive therapy, even though 
rejection is controlled [ll]. 
The use of large intravenous doses of corti- 
costeroids for reversing rejection has several 
potential advantages. A maximal circulating 
concentration of the drug can be achieved 
promptly. If the intravenous dose is adminis- 
tered intermittently, that is every 2 or 3 days, 
many of the toxic side effects of corticosteroids 
might be avoided. This would be especially 
true if it could be proved that the half-life of 
the particular corticosteroid utilized was rela- 
tively short. Considerable clinical evidence ex- 
ists from experience gained in the treatment of 
other diseases that intermittent administration 
of corticosteroids, that is every second or third 
day, is associated with fewer side effects while 
therapeutic effectiveness is maintained [8, lo]. 
Despite these potential advantages the ques- 
t,ion of the effectiveness of such a regimen for 
reversing rejection has not been verified. Only 
a few transplant teams have reported experi- 
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ence with intermittent pulse therapy to treat 
reject,ion, and little experimental evidence is 
available [2, 41. 
The half-life of methylprednisolone in dogs 
was demonstrated to be relatively short, that 
is, 31% hours, and a high maximum concentra- 
t’ion was immediately achieved. The gas chro- 
matographic method used to determine serum 
levels of methylprednisolone is specific and re- 
producible [l]. Coburg et ~2. demonstrated 
that the half-life of prednisolone is also rela- 
tively short in dogs [4]. However, they utilized 
the Porter-Silber chromagen technique which 
is less specific than gas chromatography. Col- 
lins et al. demonstrated that after oral admin- 
istration of prednisolone the peak serum level 
is usually not reached for l-2 hours, and the 
peak level is frequently only one-half the 
level reached with I-V administration of an 
equivalent dose [5]. 
When used alone there is little evidence that 
corticosteroids are able to consistently prevent 
rejection in dogs. Zukosky et al. were able to 
prolong survival of canine renal allografts by 
administering 30 mg. of prednisone per day 
[12]. On the basis of most investigators’ expe- 
rience the administration of a single dose of 
corticosteroids might not be expected to have 
much influence on the rejection process. How- 
ever, we felt that if rejection could be modified 
using a single dose of corticosteroids, this 
would be the most easily interpretible evidence 
that pulse therapy might be effective. A varia- 
tion in response was expected because of the 
antigenic disparity between donor and recipi- 
ent in an outbred population of dogs, and the 
impossibility of consistently identifying the 
same stage of rejection for administering pulse 
therapy to different animals. The reductions in 
serum and urine LDH and increases in urine 
volume and osmolality observed in most dogs, 
and the reduction in cellular infiltrates seen 
histologically in two dogs are good biologic 
evidence that a single pulse does modify rejec- 
tion. These changes occurred despite the fact 
that rejection was quite advanced at the time 
of pulse therapy in our experimental animals. 
There was no evidence of a spontaneous tend- 
ency for rejection to reverse in untreated ani- 
mals in t’his study and in other experiments in 
our laboratory. 
The dog treated with four consecutive pulses 
is especially interesting to us, but since only a 
single experiment of this type was performed, 
additional studies are needed for confirmation. 
A reduction in cellular infiltrate was not seen 
until 8 days after transplantation, and after 
the dog had received three pulses. This sug- 
gests that more than one pulse would be re- 
quired to more consitently demonstrate a his- 
tologic reduction in cellular infiltrate. The ab- 
sence of side-effects in this and the ot’her dogs 
in the experiment that received methylpredni- 
solone intravenously is somewhat surprising 
since this species is known to be quite sensitive 
to the toxic effects of corticosteroids. This lack 
of side effects is probably related to the short 
half-life of methylprednisolone. 
Kountz et al. and Bell et al. have used in- 
travenous corticosteroids to reverse rejection 
in humans [2, 61. Their favorable transplant 
survival figures indicate that this therapy is 
effective. They have utilized 1 gram of meth- 
ylprednisolone and Kountz has combined this 
therapy with other drugs such as heparin or 
actinomycin D. We have used approximately 
twice the dose of methylprednisolone as these 
investigators to treat rejection and have not 
added any adjunctive therapy. In our clinical 
experience rejection was reversed more than 
90% of the time with single or multiple pulses 
as required. No significant side effects oc- 
curred. A comparative study would be re- 
quired to determine the ideal dose of intrave- 
nous corticosteroids to reverse rejection. 
Summary 
Intravenous administration of large doses of 
methylprednisolone sodium succinate was 
demonstrated to modify rejection in both ca- 
nine and human renal allografts. One dose of 
intravenous methylprednisolone 30 mg./kg. 
administered during acute rejection in dogs re- 
sulted in an increase in urine volume and os- 
molality, and a decrease in serum and urine 
LDH. In two dogs treated with a single dose 
and in one dog treated with four consecutive 
daily doses histologic evidence of reversal of 
rejection with reduction of cellular infiltrate 
was achieved. Ninety-two percent of rejections 
encountered in 100 consecutive human recipi- 
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enta of renal allografts were halted or reversed 
with intravenous methylprednisolone 30 mg./ 
kg. given every 48-72 hours to a maximum of 
three or four doses. No significant side effects 
were observed either in dogs or humans with 
this therapy. The mean circulating half-life of 
intravenous methylprednisolone was deter- 
mined to be 3.48 * 0.7 hours in dogs. Inter- 
mittent intravenous administration of methyl- 
pretlnisolone has the potential advantage of 
being associated wit,11 fewer side effects than 
frequent oral administration and has been 
Aown to be an effective method for modifying 
rei ec tion. 
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